-
-
-
-
-
-
-
Pfizer (PFE) and BioNTech (BNTX Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
-
-
-
-
-
-
-
FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines
-
-
-
-
-
-
-
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
-
-
-
-
-
-
-
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
-
-
-
-
-
-
-
UPDATE: FDA to Hold Advisory Committee Meeting on COVID-19 Vaccines to Discuss Future Boosters
-
-
-
-
-
-
-
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
-
-
-
-
-
-
-
FDA AdCom Votes in Favor of Emergency Use Authorization for Pfizer (PFE) and BioNTech's (BNTX) Covid-19 Vaccine in Children 5 to <12 Years
-
15,959 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

